Idiopathic pulmonary fibrosis copy
-
Upload
adetunji-adesegun -
Category
Documents
-
view
95 -
download
4
Transcript of Idiopathic pulmonary fibrosis copy
![Page 1: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/1.jpg)
IDIOPATHIC PULMONARY FIBROSIS (IPF)
ADETUNJI T.A.Dept Of Medicine
OAUTHC Ile-Ife
![Page 2: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/2.jpg)
OUTLINE• INTRODUCTION• CLASSIFICATION• EPIDEMIOLOGY• AETIOLOGY• PATHOPHYSIOLOGY• CLINICAL FEATURES• DIAGNOSIS• DIFFERENTIALS• COMPLICATIONS• PROGNOSIS• CONCLUSION• REFRENCES
![Page 3: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/3.jpg)
INTRODUCTION
• Idiopathic pulmonary fibrosis (IPF) a.k.a cryptogenic fibrosing alveolitis, is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause,– primarily occurring in older adults, – limited to the lungs, – associated with histopathologic and/or radiologic pattern of
usual interstitial pneumonia (UIP)• IPF portends a poor prognosis • No proven effective therapies are available for its
treatment beyond lung transplantation.
![Page 4: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/4.jpg)
INTODUCTION2
• IPF is an interstitial lung disease (ILD)• ILDs represent a large number of conditions that
involve the parenchyma of the lung—the alveoli, the alveolar epithelium, the capillary endothelium, and the spaces between these structures, as well as the perivascular and lymphatic tissues.
• Heterogeneous group of disorders classified together because of similar clinical, roentgenographic, physiologic, or pathologic manifestions
![Page 5: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/5.jpg)
CLASSIFICATION
• ILD can be broadly classified based on major histo-pathological finding into(1) those associated with predominant inflammation
and fibrosis and (2) those with a predominantly granulomatous
reaction • Each can be subdivided into– Known cause– Unknown cause
![Page 6: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/6.jpg)
Inflammation/Fibrosis
Known Cause • Asbestosis• Fumes, gases• Drugs (antibiotics,
amiodarone, gold) and chemotherapy drugs
• Radiation• Aspiration pneumonia• Residual of acute
respiratory distress syndrome
• Smoking-related– Desquamative
interstitial pneumonia (DIP)
– Respiratory bronchiolitis–associated interstitial lung disease
– Langerhans cell granulomatosis (eosinophilic granuloma of the lung)
![Page 7: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/7.jpg)
Inflammation/Fibrosis
• Unknown Cause• Idiopathic interstitial
pneumonias (IIP)– Idiopathic pulmonary
fibrosis– Acute interstitial
pneumonia– Cryptogenic organizing
pneumonia (bronchiolitis obliterans with organizing pneumonia)
– Nonspecific interstitial pneumonia
• Connective tissue diseases– Systemic lupus
erythematosus, rheumatoid arthritis, ankylosing spondylitis, systemic sclerosis, Sjögren's syndrome, polymyositis-dermatomyositis
• Pulmonary hemorrhage syndromes– Goodpasture's syndrome,
idiopathic pulmonary hemosiderosis, isolated pulmonary capillaritis
![Page 8: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/8.jpg)
Inflammation/Fibrosis
• Lymphocytic infiltrative disorders (lymphocytic interstitial pneumonitis assd with CTD)
• Eosinophilic pneumonias• Lymphangioleiomyomatosis• Amyloidosis• Inherited diseases
– Tuberous sclerosis, neurofibromatosis, Niemann-Pick disease, Gaucher's disease, Hermansky-Pudlak syndrome
• Gastrointestinal or liver diseases (Crohn's disease, primary biliary cirrhosis, chronic active hepatitis, ulcerative colitis)
• Graft-versus-host disease (bone marrow transplantation; solid organ transplantation)
![Page 9: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/9.jpg)
Granulomatous
Known Cause • Hypersensitivity
pneumonitis (organic dusts)
• Inorganic dusts: beryllium, silica
• Unknown cause• Bronchocentric
granulomatosis
• Lymphomatoid granulomatosis
• Sarcoidosis• Granulomatous
vasculitides• Langerhans' cell
granulomatosis • Wegener's granulomatosis • Allergic granulomatosis of
Churg-Strauss
![Page 10: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/10.jpg)
EPIDEMIOLOGY
• IPF is the commonest of all Idiopathic Interstitial Pneumonias (IIPs)
• Worldwide incidence– 10.7 cases per 100,000 person-years for males and 7.4
cases per 100,000 person years for females.• Worldwide prevalence– 20 cases per 100,000 persons for males and 13 cases per
100,000 persons for females.
• Kim DS, Collard HR, King TE., Jr Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc
2006;3:285–92.
![Page 11: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/11.jpg)
EPIDEMIOLOGYUSA• Age and sex adjusted incidence
– 8.8-17.4 per 100,000 person-years a
• Prevalence– 27.4-63/100,000 person years a
• Nigeria – case reportb
• a-Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. Jan 2010;137(1):129-37• b-A rare case of cor pulmonale secondary to idiopathic pulmonary fibrosis in Nigeria Raphael Chinedu Anakwue et al
![Page 12: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/12.jpg)
EPIDEMIOLOGY
• Age– >50yrs
• Sex prevalence– >M:F (55yrs and older)
• Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. Oct 1 2006;174(7):810-6
![Page 13: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/13.jpg)
AETIOLOGY
• Remains undefined• However, some inciting agents have been
implicated– Cigarette smoking– Smoke– Environmental pollutants– Viral infections– Gastroesophageal reflux disease– Chronic aspiration– Genetic basis : <5%
![Page 14: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/14.jpg)
PATHOGENESIS
• Previous theory - generalized inflammation progressed to widespread parenchymal fibrosis.
• Current theory - IPF is an epithelial-fibroblastic disease, in which unknown endogenous or environmental stimuli disrupt the homeostasis of alveolar epithelial cells, resulting in diffuse epithelial cell activation and aberrant epithelial cell repair.
Re-establishing an intact epithelium following injury is a key component of normal wound healing.
![Page 15: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/15.jpg)
PATHOGENESIS
• In IPF, exposure to an inciting agent in a susceptible host may lead to the initial alveolar epithelial damage
• Following injury, aberrant activation of alveolar epithelial cells leading to– 1) release of potent fibrogenic cytokines and growth
factors, eg. TNF-α, TGF-β, platelet-derived growth factor, insulin-like growth factor-1, ET-1
– These are involved in the migration and proliferation of fibroblasts and the transformation of fibroblasts into myofibroblasts
![Page 16: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/16.jpg)
PATHOGENESIS
– 2) provokes the migration, proliferation, and activation of mesenchymal cells with the formation of fibroblastic/myofibroblastic foci
– myofibroblasts secrete extracellular matrix proteins
![Page 17: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/17.jpg)
PATHOGENESIS
• Failure of apoptosis leads to myofibroblast accumulation, exuberant extracellular matrix protein production, persistent tissue contraction, and pathologic scar formation
![Page 18: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/18.jpg)
PATHOGENESIS
• TGF-β has been shown to promote an antiapoptotic phenotype in fibroblasts
• Research has shown that apoptosis resistance in the fibroblasts and myofibroblasts participating in the repair of the alveolar epithelium may contribute to the persistent and/or progressive fibrosis in idiopathic pulmonary fibrosis.
![Page 19: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/19.jpg)
PATHOGENESIS
Genetic basis– Mutant telomerase
• Telomerase is a specialized polymerase that adds telomere repeats to the ends of chromosomes, helping to offset shortening that occurs during DNA replication.
• TGF-β negatively regulates telomerase activity- mutation
![Page 20: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/20.jpg)
PATHOGENESIS
• This telomere shortening could promote the loss of alveolar epithelial cells, resulting in aberrant epithelial cell repair, and therefore should be considered as another potential contributor to the pathogenesis of idiopathic pulmonary fibrosis
![Page 21: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/21.jpg)
PATHOGENESIS– MUC5B– Mucin 5B is a protein that is encoded MUC5B gene
• A common variant in the putative promoter of the gene that encodes mucin 5B (MUC5B) has been associated with the development of both familial interstitial pneumonia and sporadic pulmonary fibrosis.
• MUC5B expression in the lung was reported to be 14.1 times as high in subjects who had idiopathic pulmonary fibrosis as in those who did not.
• Therefore, dysregulated MUC5B expression in the lung may be involved in the pathogenesis of pulmonary fibrosis.
![Page 22: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/22.jpg)
PATHOGENESIS
– Surfactant protein C• Genetic mutations in serum surfactant protein
C have been discovered in some individuals with familial pulmonary fibrosis.
• These mutations in serum surfactant protein C may damage type II alveolar epithelial cells
![Page 23: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/23.jpg)
PATHOGENESIS
– Caveolin-1• Caveolin-1 limits TGF-β–induced production of
extracellular matrix proteins and restores the alveolar epithelial-repair process.
• It has been observed that the expression of caveolin-1 is reduced in lung tissue from patients with idiopathic pulmonary fibrosis.
![Page 24: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/24.jpg)
![Page 25: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/25.jpg)
CLINICAL FEATURES
• SYMPTOMS• Gradual onset, often
greater than 6 months, of dyspnea – exertional, progressive
• and/or a nonproductive cough
Systemic symptoms (uncommon)
• Weight loss• Low-grade fevers• Fatigue• Arthralgias• Myalgias
![Page 26: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/26.jpg)
CLINICAL FEATURES
• Approximately 5% of patients are asymptomatic at diagnosis – routine chest radiograph/lung biopsy
• In these group however, symptoms developed approximately 1000 days after the recognition of the radiographic abnormality a
• a-Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. Jun 2006;3(4):285-92.
![Page 27: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/27.jpg)
CLINICAL FEATURES
• It is critical to obtain a complete history, including – medication history – amiodarone, bleomycin,
nitrofurantoin– social history– occupational history– exposure history– Review of systems
• To exclude other causes of interstitial lung disease.
![Page 28: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/28.jpg)
CLINICAL FEATURES
SIGNS• Evidence of respiratory distress• fine bibasilar inspiratory crackles (Velcro
crackles). • digital clubbing(25-50%)• Cyanosis • Aside features of pulm HTN/cor pulmonale,
extra pulmonary involvement does not occur with idiopathic pulmonary fibrosis
![Page 29: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/29.jpg)
Clubbing of the fingers in idiopathic pulmonary fibrosis
![Page 30: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/30.jpg)
CLINICAL FEATURES
• FEATURES OF PULM HTN (20-40%)– loud P2 – fixed split S2, – holosystolic tricuspid regurgitation murmur,– pedal edema.– right ventricular heave– elevation of the jugular venous pressure
![Page 31: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/31.jpg)
DIAGNOSIS
• If IPF is suspected, diagnosis can be challenging
![Page 32: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/32.jpg)
DIAGNOSIS
• A Multidisciplinary Consensus Statement on the Idiopathic Interstitial Pneumonias published by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) in 2000 proposed specific major and minor criteria for establishing the diagnosis of IPF.
• However, in 2011, new simplified and updated criteria for the diagnosis and management of IPF were published by the ATS, ERS, together with the Japanese Respiratory Society (JRS) and Latin American Thoracic Association (LATA)
![Page 33: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/33.jpg)
DIAGNOSIS
Currently, a diagnosis of IPF requires:• Exclusion of known causes of ILD, e.g., domestic
and occupational environmental exposures, connective tissue disorders, or drug exposure/toxicity
• The presence of a typical radiological Usual Interstitial Pneumonia (UIP) pattern on HRCT.
• Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy
![Page 34: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/34.jpg)
IMAGING
High-resolution computed tomography• an essential component of the diagnostic
pathway in IPF• IPF is characterized by patchy, predominantly
peripheral, predominantly subpleural, and bibasilar reticular opacities
• Subpleural honeycombing (< 5-mm round translucencies with a density equal to that of air) is also a common finding
![Page 35: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/35.jpg)
Classic subpleural honeycombing (red circle) in a patient with a diagnosis of idiopathic pulmonary fibrosis
![Page 36: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/36.jpg)
IMAGING
• Ground-glass opacities can be found but are less extensive than reticular abnormalities.
• Traction bronchiectasis could also be found
![Page 37: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/37.jpg)
A patient with IPF and a confirmed histologic diagnosis of usual interstitial pneumonia. Note the reticular opacities (red circle) distributed in both lung bases and the minimal ground-glass opacities (blue circle)
![Page 38: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/38.jpg)
High-resolution computed tomography scans of the chest of a patient with IPF. The main features are of a peripheral, predominantly basal pattern of coarse reticulation with honeycombing
![Page 39: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/39.jpg)
![Page 40: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/40.jpg)
IMAGING
• Reticular opacities and honeycombing seen on HRCT imaging correlates histologically with fibrosis and honeycombing.
• The presence of subpleural honeycombing, traction bronchiectasis, and thickened interlobular septae increase the specificity of HRCT for diagnosing idiopathic pulmonary fibrosis
![Page 41: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/41.jpg)
IMAGING
• Multiple studies have documented that the accuracy of a confident diagnosis of usual interstitial pneumonia made on the basis of HRCT imaging findings by an experienced observer exceeds 90%a
• a-Misumi S, Lynch DA. Idiopathic pulmonary fibrosis/usual interstitial pneumonia: imaging diagnosis, spectrum of abnormalities, and temporal progression. Proc Am Thorac Soc. Jun 2006;3(4):307-14.
![Page 42: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/42.jpg)
IMAGING
HRCT Criteria for UIP Pattern:
– UIP pattern requires all 4 features below.• Subpleural, basal predominance• Reticular abnormality• Honeycombing with or without traction
bronchiectasis• Absence of features listed as inconsistent with
UIP pattern
![Page 43: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/43.jpg)
IMAGING
Inconsistent with UIP pattern requires any of the 7 features below.– Upper or mid-lung predominance– Peribronchovascular predominance– Extensive ground-glass abnormality (extent greater than
reticular abnormality)– Profuse micronodules (bilateral, predominantly upper lobes)– Discrete cysts (multiple, bilateral, away from areas of
honeycombing)– Diffuse mosaic attenuation/air-trapping (bilaterally, in 3 or more
lobes)– Consolidation in bronchopulmonary segment(s)/lobe(s)
![Page 44: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/44.jpg)
IMAGING
Chest Radiography• Virtually all patients with IPF have an
abnormal chest radiograph at the time of diagnosis
• lacks diagnostic specificity for idiopathic pulmonary fibrosis.
![Page 45: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/45.jpg)
IMAGING
The typical findings :• Peripheral reticular opacities (netlike linear
and curvilinear densities) predominantly at the lung bases.
• Honeycombing (coarse reticular pattern) and lower lobe volume loss can also be seen.
![Page 46: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/46.jpg)
Chest radiograph of a patient with idiopathic pulmonary fibrosis showing bilateral lower lobe reticular opacities (red circles)
![Page 47: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/47.jpg)
A chest radiograph of a patient with IPF. Note the small lung fields and peripheral pattern of reticulonodular opacification
![Page 48: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/48.jpg)
OTHER TESTS
Pulmonary function testing• Findings are nonspecific and should be used in
conjunction with clinical, radiologic, and pathologic information to ensure an accurate diagnosis
• Good for prognostication
![Page 49: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/49.jpg)
• Ventilatory pattern – Restrictive– Vital capacity, functional residual capacity, total lung
capacity, and forced vital capacity (FVC) all are reduced
– Obstructive ventilatory defect, not common; if present, may suggest the coexistence of COPD.
• Diffusion Capacity of Carbon monoxide (DLco) – Reduced– In IPF, reduced DLCO may precede the development
of abnormal lung volumes
![Page 50: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/50.jpg)
6-Minute walk testing (6MWT)• marker of functional exercise capacity that is
being increasingly used in the initial and longitudinal clinical assessment of patients with idiopathic pulmonary fibrosis
![Page 51: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/51.jpg)
• Markers of increased mortality– Patients who have >10% decline in FVC (percent
predicted) over 6 months, have a 2.4-fold increased risk of death.
– Baseline DLCO below 35% is correlated with increased mortality.
– So also decline in DLCO greater than 15% over 1 year– Desaturation below the threshold of 88% during the
6MWT
![Page 52: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/52.jpg)
Note:• in patients who do not desaturate to less than
88% during a 6-minute walk test (6MWT), the only strong predictor of mortality is a progressive decline in FVC (>10% after 6 mo)
• in patients who desaturate to less than 88% during a 6MWT, a progressive decline in DLCO (>15% after 6 mo) is a strong predictor of increased mortality
![Page 53: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/53.jpg)
• Bronchoalveolar Lavage (BAL)– not required for the diagnosis of IPF– can be useful to exclude other alternative diagnoses– may demonstrate the presence of infection,
malignancy, alveolar proteinosis, eosinophilic pneumonia, or occupational dusts.
BAL fluid neutrophilia has been demonstrated to predict early mortality.
![Page 54: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/54.jpg)
Diagnostic Value of Bronchoalveolar Lavage in Interstitial Lung Disease
Condition Bronchoalveolar lavage finding
Sarcoidosis Lymphocytosis; CD4:CD8 ratio >3.5 most specific of diagnosis
Hypersensitivity Pneumonitis Marked lymphocytosis (>50%)
Organizing Pneumonia Foamy macrophages; mixed pattern of increased cells characteristic; decreased CD4:CD8 ratio
Eosinophilic lung disease Eosinophils > 25%
Diffuse alveolar bleeding Hemosiderin-laden macrophages, red blood cells
Diffuse alveolar damage – drug toxicity
Atypical hyperplastic type II pneumocytes
Opportunistic infections Pneumocystis carinii, fungi, cytomegalovirus-transformed cells
Lymphangitic carcinomatosis, alveolar cell carcinoma, pulmonary lymphoma
Malignant cells
![Page 55: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/55.jpg)
Diagnostic Value of Bronchoalveolar Lavage in Interstitial Lung Disease
Condition BAL findings
Alveolar proteinosis Milky effluent, foamy macrophages and lipoproteinaceous intraalveolar material (periodic acid–Schiff stain–positive)
Lipoid pneumonia Fat globules in macrophages
Pulmonary Langerhans Cell Histiocytosis
Increased CD1+ Langerhans cells, electron microscopy demonstrating Birbeck granule in lavaged macrophage (expensive and difficult to perform)
Asbestos-related pulmonary disease
Dust particles, ferruginous bodies
Berrylliosis Positive lymphocyte transformation test to beryllium
Silicosis Dust particles by polarized light microscopy
Lipoidosis Accumulation of specific lipopigment in alveolar macrophages
![Page 56: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/56.jpg)
• Transthoracic Echocardiography – pulm HTN, • ECG – pulmonary HTN• Up to 30% of patients with IPF have positive
tests for ANA or rheumatoid factor; however, these titers are generally not high.– Presence of high titers may suggest the presence
of a connective-tissue disease. • CRP, ESR – may be elevated (60-94%)
![Page 57: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/57.jpg)
LUNG BIOPSY
• According to the updated 2011 guidelines, in the absence of a typical UIP pattern on HRCT, a surgical lung biopsy is required for confident diagnosis
i.e, in patients with possible UIP pattern or inconsistent with UIP pattern
• Histologic specimens for the diagnosis of IPF must be taken at least in three different places and be large enough that the pathologist can comment on the underlying lung architecture
![Page 58: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/58.jpg)
• Hence, surgical lung biopsy specimen are obtained through either an open lung biopsy or video-assisted thoracoscopic surgery (VATS)
![Page 59: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/59.jpg)
HISTOLOGY• The histopathological lesion associated with
idiopathic pulmonary fibrosis is -Usual interstitial pneumonia(UIP).
• characterized by a heterogeneous, variegated appearance with alternating areas of healthy lung, interstitial inflammation, fibrosis, and honeycomb change
• resulting in a patchwork appearance at low magnification
![Page 60: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/60.jpg)
![Page 61: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/61.jpg)
Photomicrograph of the histopathological appearances of usual interstitial pneumonia. High-power magnification (on the right) shows a focus of fibroblastic proliferation, close to an area of fibrosis within which a mild, non-specific, chronic inflammatory cell infiltrate can be observed. In the subpleural space, a typical honeycombing aspect can be recognized.
![Page 62: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/62.jpg)
• Fibrosis predominates over inflammation in usual interstitial pneumonia
• Fibroblastic foci represent microscopic zones of acute lung injury and are randomly distributed within areas of interstitial collagen deposition and
• Consist of fibroblasts and myofibroblasts arranged in a linear fashion within a pale-staining matrix.
• they represent an important diagnostic criterion
![Page 63: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/63.jpg)
UIP pattern requires all 4 criteria below.• Evidence of marked fibrosis/architectural
distortion and/or honeycombing in a predominantly subpleural/paraseptal distribution
• Presence of patchy involvement of lung parenchyma by fibrosis
• Presence of fibroblast foci• Absence of features against a diagnosis of UIP
suggesting an alternate diagnosis
![Page 64: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/64.jpg)
• Probable UIP pattern requires the following:– Evidence of marked fibrosis/architectural
distortion and/or honeycombing– Absence of either patchy involvement or
fibroblastic foci, but not both– Absence of features against a diagnosis of UIP
suggesting an alternate diagnosisOR– Honeycombing changes only
![Page 65: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/65.jpg)
• Possible UIP pattern requires all 3 criteria. – Patchy or diffuse involvement of lung parenchyma
by fibrosis, with or without interstitial inflammation
– Absence of other criteria for UIP– Absence of features against a diagnosis of UIP
suggesting an alternate diagnosis
![Page 66: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/66.jpg)
• Not UIP pattern requires any of the 6 criteria.– Hyaline membranes– Organizing pneumonia– Granulomas– Marked interstitial inflammatory cell infiltrate
away from honeycombing– Predominant airway centered changes– Other features suggestive of an alternate
diagnosis
![Page 67: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/67.jpg)
Diagnostic Considerations
• IPF– possible UIP pattern on HRCT and – UIP pattern or probable UIP pattern on surgical
lung biopsy• Probable IPF– possible UIP pattern on HRCT and – possible UIP pattern or non-classifiable fibrosis on
surgical lung biopsy
![Page 68: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/68.jpg)
• Possible IPF– a pattern inconsistent with UIP on HRCT and– UIP pattern on surgical lung biopsy
• Not IPF– a pattern inconsistent with UIP on HRCT and– probable UIP/possible UIP/ nonclassifiable fibrosis
on surgical lung biopsy– Any pattern on HRCT associated with a surgical
lung biopsy finding of not UIP
![Page 69: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/69.jpg)
DIFFERENTIAL DIAGNOSIS
• These are numerous. A few include• Other Idiopathic Interstitial Pneumonias (IIPs)– nonspecific interstitial pneumonia,– cryptogenic organizing pneumonia, – acute interstitial pneumonia– lymphoid interstitial pneumonia
![Page 70: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/70.jpg)
DIFFERENTIAL DIAGNOSIS
• Other causes of UIP pattern– Systemic sclerosis/Scleroderma– Hypersensitivity Pneumonitis– Rheumatoid Arthritis– Fibronodular Sarcoidosis– Asbestosis– Drug induced fibrosis
![Page 71: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/71.jpg)
DIFFERENTIAL DIAGNOSIS
• Other causes of Ground Glass Appearance on HRCT– Heart Failure– Non Specific Idiopathic Pneumonia (NSIP)– Desquamative Interstitial Pneumonia– Hypersensitivity Pneumonitis
![Page 72: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/72.jpg)
TREATMENT
Can be divided into
Non-pharmacologic
Pharmacologic
Surgical
![Page 73: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/73.jpg)
TREATMENT
Non-pharmacologic• Smoking cessation• Diet: healthy diet/ideal body weight improves
QOL• Long term Oxygen therapy – when SpO2<88%
or PaO2< 55mmHg• Vaccination against influenza and
pneumoccocal infections
![Page 74: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/74.jpg)
TREATMENT
Pharmacologic• Novel approaches to treatment are being
developed based on the new theories of IPF pathogenesis
• No optimal medical treatment of IPF is yet to be identified
• Hence, risk-benefit ratio important.
![Page 75: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/75.jpg)
TREATMENT
Antioxidants• N-acetyl cysteine (NAC) – gluthathione
precursor• Study of the Effects of High-Dose N-
Acetylcysteine (NAC) in IPF (IFIGENIA Idiopathic Pulmonary Fibrosis International Group Exploring N-Ace-tylcysteine I Annual)– showed improvement in Dlco and VC over 12
months of follow up
![Page 76: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/76.jpg)
TREATMENT
• Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF(PANTHER-IPF) however, worsened outcome, and increased admission rate
Biological response modulators• Etanercept (anti TNF-alpha) – no improvementEndothelin receptor antagonists• Bosentan showed no improvement in 6MWT
over placebo
![Page 77: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/77.jpg)
TREATMENT
Phosphodiesterase inhibitors• Sidenafil - no significant difference in the
6MWT• However, statistically significant differences in
the change in dyspnea, PaO2, diffusing capacity, and quality of life were noted.
![Page 78: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/78.jpg)
TREATMENT
Tyrosine kinase inhibitors• Imatinib mesylate: potent inhibitor of lung
fibroblast-myofibroblast transformation and proliferation, through inhibition of platelet-derived growth factor and transforming growth factor-β signaling – showed no significant improvement in lung function over placebo
![Page 79: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/79.jpg)
TREATMENT
Antifibrotic agents• Pirfenidone(Esbriet): a novel compound with
combined anti-inflammatory, antioxidant, and antifibrotic effects – first approved in Japan
• Approved by USA FDA in Oct 15 2014• Colchicine: no improvement in clinical
outcomeAnticoagulant: worsened outcome
![Page 80: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/80.jpg)
TREATMENT
Surgical• Lung transplantation – definitive treatment– Any patient diagnosed with IPF or probable IPF should be
referred for lung transplantation evaluation, regardless of the vital capacity
• Indication for listing– DLCO <39% predicted, – 10% or greater decrement in FVC during 6 months of follow-
up, – decrease in pulse oximetry below 88% during a 6MWT– or honeycombing on HRCT imaging
![Page 81: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/81.jpg)
COMPLICATIONS
Acute exacerbation of IPF (AE-IPF)• Commonest/most dreaded• Worsens prognosis• Rate – 10-57%• Usually secondary to infections, pulmonary
embolism, or pneumothorax
![Page 82: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/82.jpg)
COMPLICATIONS
Diagnostic criteria for an AE-IPF:• Previous or concurrent diagnosis of idiopathic pulmonary fibrosis• Unexplained worsening or development of dyspnea within 30
days• HRCT scan with new bilateral ground-glass abnormality and/or
consolidation superimposed on a background reticular or honeycomb pattern consistent with a usual interstitial pneumonia pattern
• Worsening hypoxemia from a known baseline arterial blood gas measurement
• No evidence of pulmonary infection by endotracheal aspiration or BAL
![Page 83: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/83.jpg)
OTHER COMPLICATIONS
• Pulmonary hypertension• Respiratory infection• Acute coronary syndrome• Thromboembolic disease• Adverse medication effects• Lung cancer
![Page 84: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/84.jpg)
PROGNOSIS
• Prognosis is poor• 5yr survival rate – 20-40%Poor prognostic factors
– >10% decline in FVC (% predicted) over 6 months– DLCO <35%
– A decline in DLCO >15% over 1 year – Desaturation below the threshold of 88% during the 6MWT– Progressive decline in DLCO (>15% after 6 mo)– BAL fluid neutrophilia – Male sex– Age >65
![Page 85: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/85.jpg)
CONCLUSION
• IPF is a chronic progressive fibrosing IP • Aetiology is unknown • It’s uncommon but invariably fatal• Bears semblance to a host of other disease entities• Diagnosis relies on the clinician integrating the clinical,
laboratory, radiologic, and/or pathologic features to make a clinical-radiologic-pathologic correlation that supports its diagnosis.
• No proven effective medical therapy save lung transplantation.
![Page 86: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/86.jpg)
REFERENCES
• Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. Mar 15 2011;183(6):788-824.].
• American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. Jan 15 2002;165(2):277-304.
![Page 87: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/87.jpg)
REFERENCES
• du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. Dec 15 2011;184(12):1382-9
• Wikipedia online• Medscape online• Harrison’s textbook of clinical medicine
![Page 88: Idiopathic pulmonary fibrosis copy](https://reader036.fdocuments.in/reader036/viewer/2022081506/55c46e2ebb61ebf10c8b45ad/html5/thumbnails/88.jpg)
Thank You